359
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

, , , , , , , ORCID Icon, , , & ORCID Icon show all
Pages 393-403 | Received 01 Dec 2022, Accepted 07 Jan 2023, Published online: 01 Feb 2023

References

  • Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:19. doi:10.1158/1078-0432.CCR-09-0715
  • Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi:10.1056/NEJMoa0808710
  • Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–180. doi:10.2147/JBM.S70716
  • Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4). doi:10.1111/bpa.13062
  • Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget. 2015;6(30):30295–30305. doi:10.18632/oncotarget.4497
  • Ellor SV, Pagano-Young TA, Avgeropoulos NG. Glioblastoma: background, standard treatment paradigms, and supportive care considerations. J Law Med Ethics. 2014;42(2):171–182. doi:10.1111/jlme.12133
  • Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 2016;18:v1–v75. doi:10.1093/neuonc/now207
  • Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383. doi:10.1083/jcb.201211138
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
  • Schwab DE, Lepski G, Borchers C, Trautmann K, Paulsen F, Schittenhelm J. Immunohistochemical comparative analysis of GFAP, MAP – 2, NOGO – a, OLIG – 2 and WT – 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value. Pathol Res Pract. 2018;214(1):15–24. doi:10.1016/j.prp.2017.12.009
  • Kloosterhof NK, Bralten LBC, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011;12(1):83–91. doi:10.1016/S1470-2045(10)70053-X
  • Yusoff AAM, Zulfakhar FN, Sul’Ain MD, Idris Z, Abdullah JM. Association of the IDH1 C.395G>A (R132H) mutation with histological type in Malay brain tumors. Asian Pacific J Cancer Prevent. 2016;17(12):5195–5201. doi:10.22034/APJCP.2016.17.12.5195
  • Malueka RG, Dwianingsih EK, Bayuangga HF, et al. Clinicopathological features and prognosis of Indonesian patients with gliomas with IDH mutation: insights into its significance in a Southeast Asian population. Asian Pacific J Cancer Prevent. 2020;21(8):2287–2295. doi:10.31557/APJCP.2020.21.8.2287
  • Shen G, Wang R, Gao B, Zhang Z, Wu G, Pope W. The MRI features and prognosis of gliomas associated with idh1 mutation: a single center study in Southwest China. Front Oncol. 2020;10. doi:10.3389/fonc.2020.00852
  • Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 2012;29(3):131–139. doi:10.1007/s10014-012-0090-4
  • Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443–451. doi:10.1007/s00401-013-1156-z
  • Nandakumar P, Mansouri A, Das S. The role of ATRX in glioma biology. Front Oncol. 2017;7. doi:10.3389/fonc.2017.00236
  • Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pacific J Cancer Prevent. 2015;16(2):411–420. doi:10.7314/APJCP.2015.16.2.411